An observational study in Infective Endocarditis, sponsored by Aydin Adnan Menderes University. Enrolling by invitation at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Aydin Adnan Menderes University · Observational
The main goal of this study is to evaluate the predictability of the disease by measuring the serum lubricin levels in patients with infective endocarditis and in non-patients
Infective endocarditis is a challenging disease with a wide range of clinical presentations, making it difficult to diagnose. Diagnosis primarily relies on clinical suspicion based on symptoms. Blood cultures or other microbial tests confirming the presence of infection and echocardiography are supportive diagnostic tools. Another marker that may become valuable in the near future for diagnosing infective endocarditis is Lubricin. Lubricin, a glycoprotein expressed by the PRG4 gene, has been found to have significantly elevated levels in the plasma of animals with damaged or infected heart valves compared to healthy animals. Furthermore, plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection. Lubricin and Procalcitonin will be studied from the blood samples routinely collected. During this academic study, procalcitonin and lubricin values will be measured by investigators. Thus, the sensitivity and specificity of the Lubricin parameter in patients with infective endocarditis will be evaluated.
173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.
This study's planned enrollment of 60 is below the median of 225 across 82 observational studies indexed under Endocarditis.
Browse Endocarditis studies →Aydin Adnan Menderes University is the lead sponsor of 241 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Along with 30 healthy individuals, 30 patients between the ages of 18 and 65 who meet the Duke criteria and do not receive antibiotic treatment due to infective endocarditis will be examined. Pregnant women will not be included in the study. During this examination, procalcitonin and lubricin values will be measured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients between the ages of 18-65 diagnosed with infective endocarditis according to the Duke criteria
Diagnostic Test: Lubricin
Patients between the ages of 18-65 without diagnosed with infective endocarditis according to the Duke criteria
Diagnostic Test: Lubricin
Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
Valve damage indicative sign in infective endocarditis
Concentration of Lubricin parameter have a determinative role in patients with infective endocarditis
Time frame: through study completion, an average of 2 years
Plan to share: Yes — At the end of the study, the results of the statistical analysis of all collected data will be shared
Supporting information: Study protocol, Statistical analysis plan
Start is estimated for Feb 2024; primary completion for Feb 2024, 0 months later.
Of 36 observational studies under Endocarditis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36. This study's planned 0 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aydin Adnan Menderes University →